EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Outcome 1 year after ICH: Data from the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial

Zhe Kang Law iD, Chaamanti Sivakumar Menon iD, Lisa J Woodhouse iD, Jason Philip Appleton, Rustam Al-Shahi Salman iD, Thompson Robinson, David Werring, Christine Roffe, Robert A Dineen, Philip Michael Bath, Nikola Sprigg

European Stroke Journal · 2025

DOI: 10.1177/23969873241265939 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Stroke Journal, 2025. Verfasst von Zhe Kang Law und 10 weiteren Autor:innen. Beteiligte Einrichtung: Stroke Medicine, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, UK. Hauptthemen laut MEDLINE: Tranexamic Acid, Cerebral Hemorrhage, Antifibrinolytic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Tranexamic acid for IntraCerebral Haemorrhage-2 (TICH-2) trial reported no significant improvement in death and dependency at day 90 despite reductions in haematoma expansion, early neurological deterioration and early death. However, significant recovery after stroke, particularly intracerebral haemorrhage (ICH), may take more than 3 months. Here we report the participant outcomes at 1 year after stroke. Patients and methods: TICH-2 was a prospective randomised controlled trial that tested the efficacy and safety of tranexamic acid in spontaneous ICH when given within 8 h of onset. Patients with ICH on anticoagulation were excluded. Centralised blinded telephone follow up was performed for patients from the United Kingdom at 1 year. The primary outcome was modified Rankin Scale at 1 year. Secondary outcomes included Barthel index, Telephone Interview Cognitive Status-modified, EuroQoL-5D and Zung Depression Scale. This was a prespecified secondary analysis of the TICH-2 trial.

Results

About 2325 patients were recruited into the trial (age 68.9 ± 13.8 years; 1301 male, 56%). About 1910 participants (82.2%) were eligible for day 365 follow up. 57 patients (3.0%) were lost to follow up. Tranexamic acid did not reduce the risk of poor functional outcome at 1 year (adjusted OR 0.91 95% CI 0.77–1.09; p = 0.302). However, Cox proportional hazard analysis revealed significant survival benefit in the tranexamic acid group (adjusted HR 0.83, 95% CI 0.70–0.99; p = 0.038).

Conclusion

There was no difference in functional outcome at 1 year after ICH. Tranexamic acid may reduce mortality at 1 year without an increase in severely dependent survivors. But this should be interpreted with caution as this is a result of secondary analysis in a neutral trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidCerebral HemorrhageAntifibrinolytic AgentsHumansMaleFemaleAgedMiddle AgedTreatment OutcomeProspective StudiesAged, 80 and overFollow-Up Studies

Stichwörter der Autor:innen

Intracerebral haemorrhagerandomised controlled trialsurvivaltranexamic acid

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Stroke Medicine, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham, UK.
  • Department of Medicine, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia.
  • Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
  • Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.
  • Institute of Neurology and National Hospital for Neurology and Neurosurgery, University College London, London, UK.

ORCID-Profile: Zhe Kang Law, Chaamanti Sivakumar Menon, Lisa J Woodhouse, Rustam Al-Shahi Salman

Zitieren

APA

Law, Z. K., Menon, C. S., Woodhouse, L. J., Appleton, J. P., Al-Shahi Salman, R., Robinson, T., Werring, D., Roffe, C., Dineen, R. A., Bath, P. M., & Sprigg, N. (2025). Outcome 1 year after ICH: Data from the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial. European Stroke Journal. https://doi.org/10.1177/23969873241265939

Vancouver

Law ZK, Menon CS, Woodhouse LJ, Appleton JP, Al-Shahi Salman R, Robinson T, et al. Outcome 1 year after ICH: Data from the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial. European Stroke Journal. 2025. doi:10.1177/23969873241265939

BibTeX
@article{Law2025,
  author = {Law, Zhe Kang and Menon, Chaamanti Sivakumar and Woodhouse, Lisa J and Appleton, Jason Philip and Al-Shahi Salman, Rustam and Robinson, Thompson and Werring, David and Roffe, Christine and Dineen, Robert A and Bath, Philip Michael and Sprigg, Nikola},
  title = {Outcome 1 year after ICH: Data from the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial},
  journal = {European Stroke Journal},
  year = {2025},
  doi = {10.1177/23969873241265939}
}
Kostenlos starten →